Question special
Moderator

In their 2019 JAMA article "Reconsidering the Consequences of Using Race to Estimate Kidney Function," Eneanya et al. posit that using race to guide clinical care is justified only if:
(1) the use confers substantial benefit;
(2) the benefit cannot be achieved through other feasible approaches;
(3) patients who reject race categorization are accommodated fairly; and
(4) the use of race is transparent.

Has anyone encountered an example of the use of race in clinical care that meets these criteria? How can providers and institutions be more transparent about the use of race in eGFR calculation or other clinical algorithms? How might shared decision-making be employed to lend patients agency in the use of race in their clinical care?

Eneanya ND, Yang W, Reese PP. Reconsidering the Consequences of Using Race to Estimate Kidney Function. Jama. 2019;322(2):113. doi:10.1001/jama.2019.5774